GE28-9006-54

illustra Hot Start Mix RTG 0.2ML, 480RXN

Cytiva 28900654, solid

NACRES:
NA.55

forma

solid

prazo de validade

Please be aware this product may be shipped 90 days before the expiration date. For more information on the batch specific expiration date, please contact technical service.

manufacturer/tradename

Cytiva 28900654

condição de armazenamento

(Ambient temperature in pouch with desiccant)

cor

white

Categorias relacionadas

Descrição geral

Hot Start Mix RTG is a premixed, predispensed, ambient temperature-
stable formulation that can effectively reduce nonspecific priming and primer-dimer formation during PCR. The system is based on a novel hot start method that uses a hot start activator protein to sequester primers prior to PCR, thereby making them unavailable for nonspecific priming during the reaction preparation. This method requires only a quick 2 min initial PCR activation step. In contrast, other commercially available hot start PCR kits that are based on chemical inactivation require prolonged incubation at high temperatures, which may damage the DNA template by heat-induced depurination. The net result from using Hot Start Mix RTG is a more robust and reliable amplification of the target amplicons with increased yield when compared with conventional hot start master mix products. Furthermore, the mix does not contain Taq antibody and this eliminates the risk of mammalian-source contamination.

The advantages of the Ready-To-Go (RTG) format over other hot start mixes include increased reproducibility, long-term storage at room temperature, and a more convenient reaction setup. You can expect consistent and reliable PCR results with Hot Start Mix RTG because we have minimized pipetting steps and reduced the potential for errors and contamination.
The only additional reagents required are water, primers, and template DNA. Additional MgCl2 can be easily added, allowing users to customize this reagent to their specific needs. The beads are provided predispensed into either 0.2-ml or 0.5-ml PCR tubes that are compatible with most thermal cyclers. The 0.2 ml tubes come assembled in a 96-well (8 × 12) plate format that allows individual strips of eight tubes to be easily removed. This flexibility allows use of the entire 96-well plate, strips of eight, or individual 0.2 ml tubes.

This Ready-To-Go format provides reproducible and reliable performance for demanding PCR applications in which high specificity and high sensitivity are essential to success.

Características e benefícios

Preformulated and predispensed, freeze-dried PCR reagents mix including high-quality PuReTaq DNA Polymerase and a hot start activator protein, for increased specificity and reproducibility of PCR amplifications.

Recombinant hot start activator protein sequesters primers prior to PCR, effectively reducing nonspecific priming and primer-dimer formation.
  • Avoids the risk of contamination from a mammalian source associated with hot start antibodies.
  • Quick hot start activation preserves sample integrity by avoiding extensive precycling heat treatment.
  • Streamlines the workflow and yields more reproducible results.
  • Long-term ambient-temperature stable: no freezer space required; less energy consumption for shipping and storage
  • Validated for real-time PCR.

Nota de análise

To view the Certificate of Analysis for this product, please visit www.cytiva.com.

Informações legais

illustra is a trademark of Cytiva

RIDADR

NONH for all modes of transport

Certificado de análise
Certificado de origem

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica

Redes sociais

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Pesquisa. Desenvolvimento. Produção.

Somos um fornecedor global líder para o setor de ciências biológicas, com soluções e serviços para pesquisa, desenvolvimento e produção de biotecnologia, além de produção e desenvolvimento de terapias farmacológicas com medicamentos.

© 2021 Merck KGaA, Darmstadt, Alemanha e/ou suas filiais. Todos os direitos reservados.

A reprodução não autorizada de quaisquer materiais deste site é estritamente proibida.